Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$171,210
New position
Shares Held
1,500
first reported quarter
Ownership
0.003%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026ABS Direct Equity Fund LLC holds $2,069,719 across 13 Biotechnology names. CELC ranks #6 (8.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
2,100 | $193,998 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
4,700 | $180,903 | |
| 3 | CGON |
CG Oncology, Inc.
|
2,600 | $175,968 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
1,800 | $175,050 | |
| 5 | RPRX |
Royalty Pharma plc
|
3,600 | $172,692 | |
| 6 | CELC |
Celcuity Inc.
This page
|
1,500 | $171,210 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
900 | $170,145 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
2,000 | $167,840 |
All Filings in CELC
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $171,210 | 1,500 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||